Database

Startups

Main Industry
Health Care
Main Product/Service
PuriBlood Leukocyte Reduction Filter
Leukoreduction before transfusion is proved to benefit in reducing the adverse reaction and pathogen transmission in blood transfusion since 1985.

With our patented technology, the filter can precisely capture WBCs an
The content above was translated by Ai
Founded Year
2016
Unified Business No.
42770331
Status
Active
Number of Employees
0
Total Paid-in Capital
142,300,000 (NT$)
Location of Company
Taiwan , Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups. Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed. Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
About the Company
PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center the R and D center for membrane technology. PuriBlood is committed to improving the blood filtration process with the innovative technology of zwitterionic-bias surface coating technology. Filter housing transparent housingfacilitates monitoring priming and blood flow.

The content above was translated by Ai
more ↓

Similar Companies

回頁面最頂端